NCT01234402 2019-08-14Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer PatientsEli Lilly and CompanyPhase 2 Completed153 enrolled 22 charts